In this issue
mAbs
Volume 5, Issue 3May/June 2013
View current issue
About the cover
Negative stain transmission electron microscopy (TEM) and 2D class averaging analysis of the DVD-Ig TM molecule alone (upper left) and bound to inner (lower...Continue reading
Most Popular Downloads
David Ouellette, Chris Chumsae, Anca Clabbers, et al.
Rebecca J. Rose, Patrick H.C. van Berkel, Ewald T.J. van den Bremer, et al.
Upcoming Meetings
2nd Workshop: The new ParadIgM - IgM from bench to clinic
April 23-24. 2013
Frankfurt, Germany
9th Annual PEGS
April 29-May 3, 2013
Boston, MA
3rd International Conference on Neurodegenerative Disorders: Immunotherapy and Biomarkers
May 23-24, 2013
Uppsala, Sweden
2nd International Workshop on Innovative Personalized Radioimmunotherapy
July 9-12, 2013
Nantes, France
IMmune-related Pathologies: Understanding Leukocyte Signaling and
Emerging therapies - IMPULSE 2013
August 31-September 4, 2013
Matrahaza, Hungary
Editor-in-Chief
Janice M. Reichert, Ph.D.Medline/PubMed, PubMed Central, Science Citation Index Expanded, Biotechnology Citation Index, Biological Abstracts, Biosis Previews, Scopus
Important Journal Links
Submit your manuscript to mAbs
Recommend mAbs to your library
mAbs 101 - What are mAbs?
See this section for a comprehensive and up-to-date table with FDA-approved therapeutic mAbs.
Open Access in mAbs
The cost to make an original research paper OA is $750.00 USD.
For all other types of papers, the OA fee is $500.00 USD.
Special Discounted Subscription for Antibody Society Members
'Like' mAbs on Facebook!
'Like' mAbs on Facebook to find out about newly added PDFs to forthcoming issues.
About the Journal
mAbs is an international peer-reviewed journal focused exclusively on antibodies.
Our mission is to provide a forum for communication on all topics relevant to antibody research and development, with a focus on therapeutics. In the last decade, there has been a rapid increase in antibody research and development performed by academia, government and industry located world wide. Novel antibody therapeutics are entering clinical study by commercial sponsors at an average rate of 50 per year that is predicted to continue well into the future. Over 30 mAb therapeutics have been approved and global sales of these products are approximately $40 billion. Our broad scope ensures that the journal's articles are of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community including readers concerned with technology transfer, legal issues, investment, regulatory requirements and strategic planning.
